By Abhay Ranjan & Shailesh Doshi
An increasing number of businesses are being challenged by their stakeholders regarding sustainability. In a world where businesses are facing intense challenges driven by growing complexities in their operations and compliances, demand is growing for total quality assurance solutions; solutions that extend beyond the quality and safety of products, to those that deliver sustainable solutions in the development of products and services for the present and future.
Sustainability is the core of any business. Optimized design and engineering ensures the inbuilt sustainability of the entire facility, systems and operating procedures. This becomes a qualitative competitive advantage for the industry. A scientific approach for proper and optimized design and engineering, in turn, results in overall improved performance of the business which ultimately create more avenues for sustainability and economies of scale.
It’s difficult to accept that biopharmaceutical or drugs manufacturing companies are facing issues related to sustainability.
Sustainability is a complex concept and is being used in various modes in different contexts. In this article, however, our focus is on the biopharmaceutical industry. Accordingly, in this context, sustainability means a balancing act and the ability to maintain a certain regulatory standard. Similar to Porter’s win-win hypothesis, a trade-off is not necessary. Therefore, the approach of in-built sustainability is essential when designing biopharmaceutical facilities.